Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linezolid in the treatment of subjects with complicated skin and soft tissue infections proven to be due to methicillin-resistant Staphylococcus aureus

Trial Profile

Linezolid in the treatment of subjects with complicated skin and soft tissue infections proven to be due to methicillin-resistant Staphylococcus aureus

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2015

At a glance

  • Drugs Linezolid; Linezolid; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Aug 2012 Actual patient number changed from 1052 to 1077 as reported by ClinicalTrials.gov record.
    • 12 Sep 2009 Results of a post hoc analysis were presented at ICAAC 2009.
    • 17 Dec 2008 Results were reported at ICAAC/IDSA 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top